Molecular design toward dual-modality probes for radioisotope-based imaging (PET or SPECT) and MRI
View Patent ↗In some aspects, the present invention provides novel ligands, which may be used to make novel dual-modality imaging agents, for example, for PET and MRI imaging. In further aspects, by the present disclosure also provides methods of use and methods of preparation of the novel ligands, metal complexes, and imaging agents thereof.
1. A compound of the formula:
wherein:
R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently selected from
X 1 , X 2 , and X 3 are each independently alkanediyl (C≦12) , alkenediyl (C≦12) , alkynediyl (C≦12) , arenediyl (C≦12) , heteroarenediyl (C≦12) , alkoxydiyl (C≦12) , alkylaminodiyl (C≦12) , or a substituted version of any of these groups; or
an amino acid residue, an amino acid residue linked to a targeting moiety, a PEG linker comprising between 2 and 200 repeating units;
Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , and Y 6 are each independently alkanediyl (C≦12) , alkenediyl (C≦12) , alkynediyl (C≦12) , arenediyl (C≦12) , heteroarenediyl (C≦12) , alkoxydiyl (C≦12) , alkylaminodiyl (C≦12) , or a substituted version of any of these groups; or
an amino acid residue, an amino acid residue linked to a targeting moiety, a PEG linker comprising between 2 and 200 repeating units; and
provided that all of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are not or a metal complex or salt thereof.
2. The compound of claim 1 , wherein the compound is further defined as:
or a metal complex or salt thereof.